Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?

References

• Abrams PH Fall M Cardozo L The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society Neurourol Urodyn 2002 21 2 167 178 11857671
   PubMed Web of Science ®Google Scholar
• Irwin DE Kopp ZS Agatep B Milsom I Abrams P Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction BJU Int 2011 108 7 1132 1138 21231991
   PubMed Web of Science ®Google Scholar
• Irwin DE Milsom I Hunskaar S Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 2006 50 6 1306 1314 17049716
   PubMed Web of Science ®Google Scholar
• Malmsten UG Molander U Peeker R Irwin DE Milsom I Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45–103 years Eur Urol 2010 58 1 149 156 20356669
   PubMed Web of Science ®Google Scholar
• Wennberg AL Molander U Fall M Edlund C Peeker R Milsom I A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women Eur Urol 2009 55 4 783 791 19157689
   PubMed Web of Science ®Google Scholar
• Milsom I Kaplan SA Coyne KS Sexton CC Kopp ZS Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS Urology 2012 80 1 90 96 22748867
   PubMed Web of Science ®Google Scholar
• Coyne KS Kvasz M Ireland AM Milsom I Kopp ZS Chapple CR Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States Eur Urol 2012 61 1 88 95 21831517
   PubMed Web of Science ®Google Scholar
• Wagner TH Hu TW Bentkover J Health-related consequences of overactive bladder Am J Manag Care 2002 8 Suppl 19 S598 S607 12516954
   PubMed Web of Science ®Google Scholar
• Ganz ML Smalarz AM Krupski TL Economic costs of overactive bladder in the United States Urology 2010 75 3 526 532 20035977
   PubMed Web of Science ®Google Scholar
• McGrother CW Donaldson MM Shaw C Storage symptoms of the bladder: prevalence, incidence and need for services in the UK BJU Int 2004 93 6 763 769 15049987
   PubMed Web of Science ®Google Scholar
• Andersson KE Chapple CR Cardozo L Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence Curr Opin Urol 2009 19 4 380 394 19448545
   PubMed Web of Science ®Google Scholar
• Wagg A Compion G Fahey A Siddiqui E Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience BJU Int 2012 110 11 1767 1774 22409769
   PubMed Web of Science ®Google Scholar
• Haab F Castro-Diaz D Persistence with antimuscarinic therapy in patients with overactive bladder Int J Clin Pract 2005 59 8 931 937 16033615
   PubMed Web of Science ®Google Scholar
• Buser N Ivic S Kessler TM Kessels AG Bachmann LM Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses Eur Urol 2012 62 6 1040 1060 22999811
   PubMed Web of Science ®Google Scholar
• Basra RK Wagg A Chapple C A review of adherence to drug therapy in patients with overactive bladder BJU Int 2008 102 7 774 779 18616691
   PubMed Web of Science ®Google Scholar
• Noe L Sneeringer R Patel B Williamson T The implications of poor medication persistence with treatment for overactive bladder Manag Care Interface 2004 17 11 54 60 15573804
   PubMedGoogle Scholar
• Malhotra B Guan Z Wood N Gandelman K Pharmacokinetic profile of fesoterodine Int J Clin Pharmacol Ther 2008 46 11 556 563 19000553
   PubMed Web of Science ®Google Scholar
• Khullar V Rovner ES Dmochowski R Nitti V Wang J Guan Z Fesoterodine dose response in subjects with overactive bladder syndrome Urology 2008 71 5 839 843 18342923
   PubMed Web of Science ®Google Scholar
• Nitti VW Dmochowski R Sand PK Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome J Urol 2007 178 6 2488 2494 17937959
   PubMed Web of Science ®Google Scholar
• Chapple C Van Kerrebroeck P Tubaro A Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder Eur Urol 2007 52 4 1204 1212 17651893
   PubMed Web of Science ®Google Scholar
• Sand PK Morrow JD Bavendam T Creanga DL Nitti VW Efficacy and tolerability of fesoterodine in women with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 2009 20 7 827 835 19495545
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck PE Amarenco G Thuroff JW Dose-ranging study of tolterodine in patients with detrusor hyperreflexia Neurourol Urodyn 1998 17 5 499 512 9776013
   PubMed Web of Science ®Google Scholar
• Cardozo L Amarenco G Pushkar D Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE) BJU Int 2013 111 5 804 810 23294801
   PubMed Web of Science ®Google Scholar
• Hill S Khullar V Wyndaele JJ Lheritier K Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study Int Urogynecol J Pelvic Floor Dysfunct 2006 17 3 239 247 15999217
   PubMed Web of Science ®Google Scholar
• Herschorn S Swift S Guan Z Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial BJU Int 2010 105 1 58 66 20132103
   PubMed Web of Science ®Google Scholar
• Kaplan SA Schneider T Foote JE Guan Z Carlsson M Gong J Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial BJU Int 2011 107 9 1432 1440 20860717
   PubMed Web of Science ®Google Scholar
• Piault E Evans CJ Espindle D Kopp Z Brubaker L Abrams P Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire Neurourol Urodyn 2008 27 3 179 190 17565727
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ Goldfischer ER Morrow JD Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study Int J Clin Pract 2009 63 4 560 567 19348029
   PubMed Web of Science ®Google Scholar
• Cardozo L Kaplan S Herschorn S A Randomised Controlled Trial of Fesoterodine in Subjects with Overactive Bladder and Suboptimal Response to Tolterodine Extended Release: Results from the AFTER Study European Association of Urology (EAU) Annual Meeting March 15–19, 2013 Milan, Italy Abstract 740
   Google Scholar
• Coyne K Revicki D Hunt T Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q Qual Life Res 2002 11 6 563 574 12206577
   PubMed Web of Science ®Google Scholar
• Castro D Miranda P Sánchez-Ballester F Arumi D Lizarraga I Ebel C grupo de estudio Impacta [Assessment of reasons for overactive bladder treatment change] Actas Urol Esp 2011 35 2 73 79 Spanish 21296454
   PubMed Web of Science ®Google Scholar
• Colman S Chapple C Nitti V Haag-Molkenteller C Hastedt C Massow U Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder Urology 2008 72 4 803 807 18722655
   PubMed Web of Science ®Google Scholar
• Ginsberg D Schneider T Kelleher C Efficacy of fesoterodine compared with extended release tolterodine in men and women with overactive bladder BJU Int 2013 112 3 373 385 23826844
   PubMed Web of Science ®Google Scholar
• Wagg A Khullar V Marschall-Kehrel D Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial J Am Geriatr Soc 2013 61 2 185 193 23350833
   PubMed Web of Science ®Google Scholar
• Wagg A Khullar V Michel MC Oelke M Darekar A Bitoun CE Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial Neurourol Urodyn 3 4 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Dubeau CE Kraus SR Griebling TL Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo-controlled trial J Urol 8 31 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Wagg A The cognitive burden of anticholinergics in the elderly – implications for the treatment of overactive bladder Eur Urol Rev 2012 7 1 42 49
   Google Scholar
• Katz IR Sands LP Bilker W DiFilippo S Boyce A D’Angelo K Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride J Am Geriatr Soc 1998 46 1 8 13 9434659
   PubMed Web of Science ®Google Scholar
• Kay GG Maruff P Scholfield D Evaluation of cognitive function in healthy older adultss treated with fesoterodine Neurourol Urodyn 2011 30 6 961 963
   Web of Science ®Google Scholar
• Folstein MF Robins LN Helzer JE The Mini-Mental State Examination Arch Gen Psychiatry 1983 40 7 812 6860082
   PubMed Web of Science ®Google Scholar